Mind Medicine Inc - Ordinary Shares (Sub Voting) is a premium stock of StocksGuide. Please log in to activate an alert for Mind Medicine Inc - Ordinary Shares (Sub Voting).
Register for Free
Please register for free to add Mind Medicine Inc - Ordinary Shares (Sub Voting) to your portfolio.
Mind Medicine Inc - Ordinary Shares (Sub Voting) Stock News
Mind Medicine (MNMD 2.81%), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed the highly specialized enterprise's share price higher, to the point where it closed the month up almost 14% in price.
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: Jefferies Global Healthcare Conference Format: Pres...
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's exec...
Investors had a good mind to plow money into Mind Medicine (MNMD 8.13%) stock on Tuesday. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by rising more than 8% in price on a legislative development.
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 53,350 common shares of the Compan...
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at the 2025 RBC Capital Markets Global Healthcare Conference: 2025 RBC Capital Markets Global Healthcare...
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive Officer Matt Wiley - Chief Commercial Officer Dan Karlin - Chief Medical Officer Conference Call Participants Madhu Yennawar - Leerink Partners Brian Abrahams - RBC Capital Markets Elaine Kim - Can...
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and provided an update on business highlights. “We are proud to share that all three of our pivotal Phase 3 tri...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.